Business Overview: Gyre Therapeutics, Inc. (NASDAQ: GYRE)

---

Executive Summary

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on small-molecule therapies for organ fibrosis and related inflammatory diseases. The company is incorporated in Delaware and headquartered in San Diego, but nearly all of its commercial revenue today is generated in the People's Republic of China (PRC) through its majority-owned subsidiary, Beijing Continent Pharmaceuticals (doing business as Gyre Pharmaceuticals).

Gyre matters because it holds one of the few approved, reimbursed therapies for idiopathic pulmonary fibrosis (IPF) in the world's second-largest pharmaceutical market, and because it is actively trying to convert that PRC commercial base into a US-facing pipeline. In March 2026 the company completed a merger with Cullgen Inc., explicitly positioned to create "a fully integrated, US- and China-based biopharmaceutical company" — a structural pivot that will reshape its risk and opportunity profile going forward.

---

1. Core Business Model & How They Work

Gyre's business model is a hybrid of mature PRC commercial pharma and early-stage US clinical biotech:

[ China: Approved, NRDL-Listed Drugs ] ➡️ [ Hospital/Pharmacy Distribution ] ➡️ [ Recurring Chronic-Therapy Revenue ]
[ US/Global: Pipeline (Hydronidone, F-series) ] ➡️ [ Clinical Trials ] ➡️ [ NDA/IND Filings ] ➡️ [ Future Approvals ]

The PRC side generates real, recurring cash flow from chronic-disease patients already on therapy; the US/global side is a classic biotech R&D bet funded in part by that PRC cash flow and by equity markets (Nasdaq-listed).

---

2. Business Segments

Gyre does not report formal multi-segment financials, but operationally splits into two areas:

┌───────────────────────────────┐
│      Gyre Therapeutics, Inc.   │
└────────────────┬────────────────┘
                  │
       ┌──────────┴──────────┐
       ▼                     ▼
┌──────────────────┐  ┌──────────────────────┐
│  PRC Commercial    │  │  US/Global Pipeline   │
│  (Gyre Pharma)      │  │  (Hydronidone, F-series) │
│  ~100% of revenue   │  │  Pre-revenue           │
└──────────────────┘  └──────────────────────┘

PRC Commercial sells three marketed, NRDL (National Reimbursement Drug List)-listed products into Chinese hospitals and pharmacies. US/Global Pipeline is pre-revenue, centered on Hydronidone for liver fibrosis and a MASH program, now folded into the enlarged post-Cullgen pipeline.

---

3. Product Portfolio

---

4. Competitive Landscape

IPF in China: ETUARY's share has eroded as Boehringer Ingelheim's OFEV (nintedanib) has grown (~$76.9M in PRC sales in 2024). Gyre's response was to launch its own nintedanib product (Etorel), effectively competing with itself and the originator at once — an unusual but pragmatic defensive move in a market with real barriers to entry (reimbursement listing, physician relationships, manufacturing approval).

MASH (US, pipeline-stage): Madrigal Pharmaceuticals' Resmetirom is the first FDA-approved MASH therapy and the benchmark Gyre's future US candidates would be measured against; additional competition comes from GLP-1 agonists, FGF21 analogs, and thyroid hormone receptor-β agonists from much larger players.

Gyre competes primarily on efficacy, safety, dosing convenience, pricing, and reimbursement status rather than on scale or brand breadth.

---

5. Strategic Strengths & Risks

Strengths

• First-mover, reimbursed position in PRC organ fibrosis: ETUARY's NRDL listing and long track record give it durable hospital formulary access that a new entrant would need years to replicate.
• Diversified PRC revenue base: three marketed products across pulmonary fibrosis, liver disease, and thrombocytopenia reduce single-product dependence.
• Hydronidone optionality: a Phase 3 success in a large, underserved indication (hepatitis B-associated liver fibrosis) could be a meaningful new revenue stream.

Risks

• PRC centralized drug procurement: Beijing's volume-based procurement programs routinely compress prices on listed drugs, a direct and recurring pressure on ETUARY, Etorel, and Contiva margins.
• Cullgen merger integration: combining a PRC-commercial company with a US-clinical-stage biotech (and associated termination-fee and litigation risk around the deal itself) is execution-heavy.
• Single-market concentration: essentially all revenue today originates in China, exposing the company to PRC-specific regulatory, pricing, and geopolitical risk (including BIOSECURE Act-related supply chain scrutiny, given its reliance on WuXi STA for API manufacturing).
• Nasdaq listing and financing risk: continued US listing and the capital needs of a dual US/China pipeline remain open items.

---

6. Financial Overview

---

7. Summary Conclusion

Gyre Therapeutics is best understood as a profitable, reimbursed PRC organ-fibrosis franchise using its cash generation to fund a US-facing pipeline bet, now accelerated by the Cullgen merger. Its moat rests narrowly but genuinely on NRDL-listed, first-mover access in a regulated market with real approval and reimbursement barriers — not on patents that would hold up globally or on switching costs that extend beyond China. The central question for the business is whether Hydronidone's hepatitis B liver fibrosis data and the newly combined US/China pipeline can diversify the company past its PRC concentration before procurement-driven pricing pressure erodes the legacy ETUARY franchise further.